BCL2L1 and B-cell chronic lymphocytic leukemia: Initially, it showed antitumor activity in CLL and FL in early phase clinical trials, but further studies were halted because of its on target BCL-xL inhibition in platelets leading to acute thrombocytopenia51,52.